Is KPV legal in the UK?

It is supplied as a material for laboratory research. It is not a licensed medicine and cannot be prescribed or dispensed.

Why is the anti-inflammatory literature a compliance risk?

Because the vocabulary of the research is already the vocabulary of an indication, which makes sliding from reporting a study to implying a treatment unusually easy.

Are there registered trials?

None established. There is no human clinical data for KPV.

KPV

KPV Regulatory Status

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

KPV holds no marketing authorisation from the MHRA, EMA or FDA and has not been through regulatory review in any jurisdiction. There is no registered interventional trial programme and no human clinical data, so it is supplied for laboratory research only, with no claim made about inflammation or any condition in any person.

Key facts

MHRA status: Not authorised
EMA status: Not authorised
FDA status: Not approved
Clinical trials: None established
UK supply basis: Laboratory research only
Specific risk: Anti-inflammatory indication language

The position

No regulator has assessed KPV. There is no marketing authorisation in any jurisdiction, no registered interventional trial programme, and no route by which laboratory research material becomes a medicine. It is supplied here on the same basis as everything else in the catalogue.

Why this category's literature is a particular hazard

The published work is anti-inflammatory and includes colitis models — research framed around a disease. That framing makes it unusually easy to slide from reporting a study to implying a treatment, because the vocabulary of the literature is already the vocabulary of an indication. The distance between mice with induced colitis and a person with inflammatory bowel disease is the whole distance that matters.

Research material referenced

KPV 10mg — third-party HPLC tested

View — £24.99

What is said here and what is not

Reported: that KPV is the C-terminal tripeptide of alpha-MSH, that studies describe effects on NF-κB signalling and cytokine production in cell culture, and that a 2008 paper reported anti-inflammatory potential in murine colitis. Not said: that it treats, reduces or affects inflammation in any person. The first set is fact about published work; the second would be a therapeutic claim.

The enforcement context

The MHRA opened investigations into UK retailers making therapeutic claims about unregulated peptide products in April 2026. The framework turns on the claim and the intended use rather than the compound, and an anti-inflammatory claim about a research chemical is squarely within what it addresses.

What would change the position

An application to and assessment by the MHRA. For KPV that would first require the clinical development that does not currently exist — no registered trials, no human data, and no defined molecular target.

Extended research context

The KPV deep dive

Deep dive: two functions in one hormone, and the case for splitting them

Alpha-MSH is a thirteen-residue peptide cleaved from proopiomelanocortin, and it does two things that have almost nothing to do with each other. Its core sequence engages melanocortin receptors on melanocytes and drives melanin synthesis - the activity it is named for. Separately, it carries anti-inflammatory activity that Brzoska and colleagues localised to its C-terminal end, a paper titled 'terminal signal' precisely because the finding was that the signal sits at the terminus rather than in the receptor-binding core. That is an unusually clean functional separation, and it produced two research compounds pulling in opposite directions from one parent. KPV takes the C-terminal three residues and discards the pigmentation activity. Melanotan II does the reverse - a cyclic analogue built around the receptor-binding portion to maximise exactly what KPV was designed to leave behind. Same hormone, opposite halves.

Deep dive: what happens when you shrink a molecule fivefold

Going from alpha-MSH at 1,664.9 Da to KPV at 342.43 Da is not a trim, it is a change of category. A 1,665 Da peptide is firmly a cell-surface ligand - far too large to cross a membrane passively, so whatever it does must begin at a receptor. A 342 Da tripeptide is small enough that intracellular access becomes plausible, which is why KPV's reported mechanism is described in terms of NF-kappaB signalling rather than melanocortin receptor engagement. The consequence is rarely stated: if the fragment acts inside the cell and the parent acts at its surface, then the anti-inflammatory activity of the two is not necessarily the same phenomenon, and read-across between them should run cautiously in both directions. Fragment logic assumes the fragment is the parent minus something. Here it may be the parent minus something plus a different route of access.

Deep dive: the delivery paper is the most informative thing in the literature

Xiao and colleagues published in Molecular Therapy in 2017 on delivering KPV orally using hyaluronic acid-functionalised nanoparticles targeted to inflamed intestinal tissue. Read as a result it is a delivery success. Read as a statement about the compound it is more interesting: nobody builds a targeted nanoparticle carrier for a molecule that already reaches its target. The existence of that work says the free tripeptide's arrival at inflamed tissue was the limiting problem - which follows directly from being 342 Da, highly soluble and rapidly cleared. It is the same signal that CJC-1295's DAC modification carries for growth hormone secretagogues, or that lipidation carries across the whole incretin class: when the engineering effort goes into getting a compound to stay and arrive rather than into making it more active, the pharmacokinetics were the bottleneck.

Research applications

▸Melanocortin fragment structure-activity research
▸NF-kappaB pathway and cytokine production studies in culture
▸Murine models of induced intestinal inflammation
▸Targeted peptide delivery and carrier system development
▸Comparative work on parent hormones and isolated fragments
▸Analytical method development for very short peptides

Handling checklist

✓Verify identity against Lys-Pro-Val, CID 125672, at 342.43 Da
✓Do not search PubChem for 'KPV' - it returns an unrelated organic acid
✓Store lyophilised, cold, dry and dark
✓Use low-binding consumables; a small cationic peptide adsorbs to surfaces
✓Reconstitute gently down the vial wall and swirl, never shake
✓Aliquot into single-use volumes to avoid freeze-thaw cycling
✓Expect no disulfide or oxidation satellites - no cysteine, no methionine

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Searching PubChem for 'KPV' to verify a certificate

Fix: That returns CID 13294447, 2-oxo-5-phenylpentanoic acid at 192.21 Da, an unrelated compound. Search Lys-Pro-Val for CID 125672.

✗ Treating KPV and alpha-MSH findings as interchangeable

Fix: They differ fivefold in mass and the fragment may act intracellularly where the parent cannot. Read across cautiously in both directions.

✗ Assuming a colitis model result speaks to inflammatory bowel disease

Fix: Induced colitis in a mouse is acute and chemical; human IBD is chronic, heterogeneous and immunologically complex.

✗ Expecting to quantify KPV by absorbance at 280 nm

Fix: There is no aromatic residue in the sequence, so there is no usable absorbance there.

✗ Attributing unexplained low recovery to degradation

Fix: KPV is chemically robust - no cysteine, methionine or asparagine. Adsorption to glass and plastic is the more likely cause.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is KPV legal in the UK?: It is supplied as a material for laboratory research. It is not a licensed medicine and cannot be prescribed or dispensed.
Why is the anti-inflammatory literature a compliance risk?: Because the vocabulary of the research is already the vocabulary of an indication, which makes sliding from reporting a study to implying a treatment unusually easy.
Are there registered trials?: None established. There is no human clinical data for KPV.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum